| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
| CZ20012406A3 (en) | 1999-01-07 | 2002-03-13 | Lexigen Pharmaceuticals, Corp. | Expression and export of proteins acting against obesity such as Fc fusion proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| PT1355942E (en) | 2000-12-07 | 2008-11-21 | Lilly Co Eli | Glp-1 fusion proteins |
| JP4524074B2 (en) | 2001-03-09 | 2010-08-11 | アーナソン， バリー ジー． | Polymeric immunoglobulin fusion proteins targeting low affinity Fcγ receptors |
| JP4422949B2 (en) | 2001-06-26 | 2010-03-03 | 武田薬品工業株式会社 | TGF-β superfamily production / secretion promoter |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US7101852B2 (en) | 2003-05-30 | 2006-09-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment and prevention of restenosis |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| US7736653B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| JP5448338B2 (en) | 2004-04-13 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | How to regulate appetite |
| US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| CN1974601A (en) | 2005-11-28 | 2007-06-06 | 上海新生源医药研究有限公司 | New-type Fc fusion protein and its production process |
| JP2010500876A (en) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling |
| EP2783698A1 (en) | 2007-08-16 | 2014-10-01 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| JP2011523051A (en) | 2008-05-20 | 2011-08-04 | エフ．ホフマン−ラ ロシュ アーゲー | GDF-15 as a biomarker in type 1 diabetes |
| CA2732449A1 (en) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| ES2434996T3 (en) | 2008-10-31 | 2013-12-18 | St Vincent's Hospital Sydney Limited | Prognosis methods in chronic kidney disease |
| ES2688978T3 (en) | 2009-11-23 | 2018-11-07 | Amgen Inc. | Fc monomeric antibody |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| EP2679234A3 (en) | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| EP3225994A1 (en) | 2010-08-26 | 2017-10-04 | Roche Diagnostics GmbH | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
| EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
| PT2635607T (en) | 2010-11-05 | 2019-12-11 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain |
| JP5972915B2 (en) | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Fc variant |
| AU2012240102C1 (en) | 2011-04-08 | 2016-09-08 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
| EA201892619A1 (en) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| KR20140125803A (en)* | 2012-01-26 | 2014-10-29 | 암젠 인크 | Growth differentiation factor 15(gdf-15) polypeptides |
| CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| CN104520320B (en) | 2012-04-20 | 2018-05-01 | 美勒斯公司 | For producing the ways and means of immunoglobulin-like molecule |
| AR094271A1 (en) | 2012-12-21 | 2015-07-22 | Aveo Pharmaceuticals Inc | ANTI-BODY ANTIBODIES |
| BR112015018104A2 (en)* | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | modified gdf15 polypeptides, their use, compositions comprising them and sterile container comprising said compositions |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| TN2016000035A1 (en) | 2013-07-31 | 2017-07-05 | Amgen Inc | Growth differentiation factor 15 (gdf-15) constructs |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| ES2818109T3 (en) | 2014-06-23 | 2021-04-09 | Novartis Ag | Site-specific protein modifications |
| US20170204149A1 (en) | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
| EP3160496B1 (en) | 2014-06-24 | 2021-03-03 | Novo Nordisk As | MIC-1 FUSION PROTEINS AND USES THEREOF |
| EA035581B1 (en) | 2014-07-30 | 2020-07-10 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Compositions and methods of use for treating metabolic disorders |
| WO2016069921A1 (en) | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| CN108367053A (en)* | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | The method that metabolic disease is treated or improved using growth and differentiation factor 15 (GDF-15) |
| CA3015660A1 (en) | 2016-03-04 | 2017-09-08 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| PE20190117A1 (en) | 2016-05-24 | 2019-01-16 | Novo Nordisk As | COMPOUNDS OF MIC-1 AND USES OF THEM |
| TWI724392B (en) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | Growth differentiation factor 15 agonist compounds and methods of using the same |
| JP7058670B2 (en) | 2018-04-09 | 2022-04-22 | アムジエン・インコーポレーテツド | Proliferation differentiation factor 15 fusion protein |
| MX2021010737A (en) | 2019-03-08 | 2021-09-28 | Amgen Inc | COMBINATION THERAPY BY GROWTH DIFFERENTIATION FACTOR 15. |